David Giljohann is the founder of Exicure. Exicure has raised $100M in total funding. Latest round: Series C. Based in Chicago, United States.
David Giljohann is a biotechnology entrepreneur who founded Exicure in 2011 as its founding scientist and became CEO in 2013, leading the Chicago-based company to develop immunotherapy drugs using Spherical Nucleic Acid technology. He co-founded Exicure with Chad Mirkin and Shad Thaxton, raising over $100 million in funding.
Full founder directory · Investor directory · Company funding database · Fundraising library